Sarah Kiely
Contacto de Relaciones con Inversores en PROQR THERAPEUTICS N.V. .
Origen de la red de primer grado Sarah Kiely.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Subsidiary | Biotechnology | 26 | |
| Public Company | Pharmaceuticals: Major | 16 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Sarah Kiely a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Impatients NV
 Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | Miscellaneous Commercial Services | Founder Chairman Human Resources Officer | |
| SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Graduate Degree Doctorate Degree | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Treasurer | |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Undergraduate Degree Graduate Degree | |
| University of Leiden | College/University | Corporate Officer/Principal Graduate Degree | |
| LOGICBIO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Operating Officer | |
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member Founder | |
| Virginia Polytechnic Institute & State University | College/University | Graduate Degree Undergraduate Degree | |
| University of Massachusetts | College/University | Doctorate Degree Undergraduate Degree | |
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Miscellaneous Commercial Services | Chief Executive Officer Corporate Officer/Principal | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Public Communications Contact | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree | |
Leyden Laboratories B.V.
 Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Miscellaneous Commercial Services | Founder Director/Board Member | |
Deluxe Business Operations, Inc.
 Deluxe Business Operations, Inc. Commercial Printing/FormsCommercial Services Deluxe Business Operations, Inc. used to design and produce printed products. The company products are business forms, checks, envelopes, labels and greeting cards, retail merchandising aids, packaging, shipping and warehouse supplies. The company was founded in 1952 and was headquartered in Groton, MA. | Commercial Printing/Forms | Director of Finance/CFO Comptroller/Controller/Auditor | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Chief Executive Officer Investor Relations Contact | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| AVEO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| The Pennsylvania State University | College/University | Corporate Officer/Principal Masters Business Admin | |
Aescap Venture Management BV
 Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Investment Managers | Founder Private Equity Investor | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Human Resources Officer | |
| University of Amsterdam | College/University | Graduate Degree Graduate Degree | |
Domantis Ltd.
 Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Pharmaceuticals: Major | Director of Finance/CFO Chairman | |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| LYRA THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
AstraZeneca Pharmaceuticals LP
 AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Medical Specialties | Director/Board Member | |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Yale University | College/University | Undergraduate Degree | |
| RADIUS HEALTH, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| Colorado State University | College/University | Undergraduate Degree | |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Graduate Degree | |
Bowdoin College
 Bowdoin College Other Consumer ServicesConsumer Services Bowdoin College is an independent, nonsectarian, coeducational residential, undergraduate liberal arts institution founded in 1794. It is located in Brunswick, ME. | College/University | Undergraduate Degree | |
| CELYAD ONCOLOGY SA | Biotechnology | Chief Tech/Sci/R&D Officer | |
| SURROZEN, INC. | Biotechnology | Director/Board Member | |
| THERMO FISHER SCIENTIFIC | Medical Specialties | Public Communications Contact | |
| DYNE THERAPEUTICS, INC. | Biotechnology | Investor Relations Contact | |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member |
Estadísticas
Internacional
| Estados Unidos | 37 |
| Países Bajos | 8 |
| Reino Unido | 5 |
| Irlanda | 2 |
| Canadá | 2 |
Sectorial
| Health Technology | 32 |
| Consumer Services | 13 |
| Commercial Services | 6 |
| Finance | 3 |
Operativa
| Director/Board Member | 145 |
| Corporate Officer/Principal | 85 |
| Independent Dir/Board Member | 63 |
| Undergraduate Degree | 30 |
| Chief Tech/Sci/R&D Officer | 29 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Howard H. Pien | 27 |
| Alison Lawton | 25 |
| James Shannon | 23 |
| Mark B. Skaletsky | 18 |
| Nicole Onetto | 17 |
| Gregory Perry | 16 |
| Theresa Heggie | 16 |
| Domenico Valerio | 15 |
| Mark Enyedy | 15 |
| Blaine McKee | 13 |
| James G. Stout | 13 |
| René Beukema | 13 |
| Jennifer Herron | 12 |
| David B. Johnston | 11 |
| Anna Berkenblit | 11 |
- Bolsa de valores
- Insiders
- Sarah Kiely
- Conexiones Empresas
